MAIA Biotechnology, Inc. (MAIA) Dividend History

Company News

• MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients - Benzinga

  MAIA Biotechnology's lung cancer drug THIO, sequenced with Regeneron's cemiplimab, has shown promising long-term benefits in advanced non-small-cell-lung-cancer patients who failed previous treatments. The treatment has been well-tolerated with lower toxicity than standard-of-care, and some patients have continued the treatment for over 12 months, demonstrating safety, efficacy, and ongoing benefits.

  Benzinga

  Featured Companies: REGN
• MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

  CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).

  GlobeNewswire Inc.
• MAIA Soars 20% on Interim Results From Lung Cancer Study

  MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.

  Zacks Investment Research

  Featured Companies: CTMX REGN